PRNewsWire
06 May 2026, 20:05 UTC · 22w ago
Castle Biosciences Reports First Quarter 2026 Results
Impact · against what's priced in
Castle Biosciences is showing strong operational momentum with a guidance raise and significant growth in TissueCypher volumes. The combination of top-line growth and a robust cash position of $261.7 million makes the Q1 results a positive catalyst.
- CSTL+0.60
No priced-in read yet
- In context
The company raised its 2026 revenue guidance to $345-355 million and reported a 36% year-over-year increase in core test reports, driven largely by a 58% jump in TissueCypher volumes.
Read from the article alone
Search tags
